Goal
Participants should be able to recognize the role of renal denervation as a treatment for uncontrolled or resistant hypertension within advanced hypertension management plans and discuss emerging data related to renal denervation and patient management care plans.

Learning Objectives

1. Discuss the latest clinical trial data and guidelines for renal denervation as a treatment for uncontrolled hypertension.
2. Evaluate advanced hypertension management care plans and team-based care approaches for when to consider renal denervation treatment.
3. Explain how renal denervation may impact the hypertensive patient management care continuum, including roles of the healthcare team, reimbursement, and procedural considerations.

Target Audience

• General cardiologists
• Hypertension specialists
• Advanced practice providers including nurse practitioners, physician associates and pharmacists

Co-Chairs

Joseph Ebinger, MD, MS, FACC
Associate Professor of Cardiology
Director, Cardiac Critical Care
Director, Clinical Analytics
Smidt Heart Institute, Cedars-Sinai Medical Center
Los Angeles, CA USA
Consultant Fees/Honoraria: Edwards LifeSciences
Research/Research Grants: Edwards LifeSciences

Eugene Yang, MD, MS, FACC
Clinical Professor of Medicine, Division of Cardiology
Carl and Renée Behnke Endowed Chair for Asian Health
University of Washington School of Medicine
Medical Director, UW Medicine Eastside Specialty Center Heart Institute
Co-Director, UW Medicine Cardiovascular Wellness and Prevention Program
Seattle, WA USA
Consultant Fees/Honoria: Chroma, Genentech, Inc., Idorsia, Mineralys, Qure, Sky Labs, American College of Cardiology
Ownership Interests/Partnership/Principal: Measure Labs, TenPoint7
Research/Research Grants: Microsoft

Faculty

Beth L Abramson MSc, MD, FACC
Paul Albrechtsen Professor of Preventive Cardiology & Women's CV Health
Division of Cardiology, St. Michael's Hospital
University of Toronto
Toronto, Canada
Other (Infrastructure Support for a Cardiometabolic Clinic): Amgen Inc., Bayer Healthcare Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals Inc., his therapeutics, Janssen Pharmaceuticals Inc., Novartis Corporation, Novo Nordisk Inc.

Branko Beleslin, FACC
Full Professor, Internal Medicine/Cardiology
Head, PhD Studies, Investigations in Cardiovascular Medicine
Medical Faculty, University of Belgrade
Head, Department for Functional Diagnostics and Hemodynamics
Cardiology Clinic, University Clinical Center of Serbia
Medical Faculty, University of Belgrade
Governor. ACC Consortium Chapter for the Republic of Serbia and Republic Srpska
Belgrade, Serbia
Dr. Beleslin has disclosed that he has no actual or potential conflicts of interest in regards to this program.

Eileen Handberg, PhD, ARNP, BC, FACC
Research Professor of Medicine
Director, College of Medicine Clinical Research Hub
Director, Clinical Trials Program
Program Director, Florida CARES & CAP
University of Florida
Gainesville, FL USA
Consultant Fees/Honoraria: Sonofi, Novo Nordisk Inc., Milestone Pharmaceuticals, Preventative Cardiovascular Nurses Association
Research/Research Grants: Abbott, Abbott Laboratories, Ablative Solutions Inc., AHA Biocardia, DOD, Evaheart Inc., NIH, PCORI

Tiffany C. Randolph, MD, MHA, FACC
Director, Heart and Vascular Center for Prevention
Director, Advanced Hypertension Clinic
Cone Health Heart and Vascular
Greensboro, NC USA
Consultant Fees/Honoraria: Medtronic
Speaker's Bureau: Edwards Lifesciences, ReCor Medical

Eric A. Secemsky, MD, MSc, FACC,
Director, Vascular Intervention, Beth Israel Deaconess Medical Center
Section Head, Interventional Cardiology and Vascular Research, Richard A. and Susan F. Smith Center for Outcomes Research, Beth Israel Deaconess Medical Center
Associate Professor of Medicine, Harvard Medical School
Boston, MA USA
Consultant Fees/Honoraria: Abbott Laboratories, Bayer Healthcare Pharmaceuticals, Boston Scientific, Cordis, CSI, Endovascular Engineering, Gore, Inari, InfraRedx, Janssen Pharmaceuticals Inc., Medtronic, Philips, Rampart, RapidAI, Shockwave, Siemens, Teleflex, Terumo, Venture Medical Group, Zoll
Research/Research Grants: Abbott Laboratories, AstraZeneca Pharmaceuticals, BD Bard, Boston Scientific, Cook, CSI, Laminate Medical, Medtronic, Philips
Speaker's Bureau: BD Bard, Cook

Toniya Singh, MBBS, FACC
Managing Partner St Louis Heart and Vascular
Governor Elect, Missouri Chapter of the ACC
Chair, National Cardiovascular Management Council of the ACC
St Louis, MO USA
Stock: Heart and Vascular Partners

Registration is free. However, seats are limited so make sure to register for in-person participation today. The program starts with a complimentary lunch at noon.

If you are experiencing issues with registration, call Member Care at 800-253-4636 or 202-375-6000.

This course will be held at the Marriott Marquis Chicago in Grand Horizon E and F.

The hotel is adjacent to McCormick Place Convention Center in Chicago.

The address is:
2121 South Prairie Avenue
Chicago, Illinois, 60616

Credit Designation Statement:
The following types of credit are available for attending this in-person course:

• Physicians: The ACCF designates this internet enduring material for a maximum of 2.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
• Nurses: The ACCF designates this educational activity for a maximum of 2.25 continuing nursing education contact hours.
• Physician Associates: The American College of Cardiology Foundation has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 2.25 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.
• Interprofessional Continuing Education (ICPE) Credit: This activity was planned by and for the healthcare team, and learners will receive 2.25 Interprofessional Continuing Education (IPCE) credits for learning and change.

Credit and Course Evaluation:
Your feedback from this American College of Cardiology (ACC) educational course will help us to better target ACC educational initiatives and efforts to support you and your future learning needs.

In order to receive your CME, CNE, AAPA and/or ICPE certificate or certificate of attendance, you must complete a brief evaluation survey online. This survey will be sent via email and will include a direct link to the survey.

We strongly recommend that evaluations and credit claims be submitted within one month of the course, but you must complete them within three months of the course.

Disclaimer Statement:
This information is provided for general medical education purposes only and is not meant to substitute for the independent medical judgment of a clinician relative to diagnostic and treatment options for a specific patient’s medical condition.

The American College of Cardiology Foundation (ACCF) does not warrant the completeness, accuracy or usefulness of any opinions, advice, services or other information provided through this activity. In no event will ACCF be liable for any decision made, or action taken, in reliance upon the information provided through this activity.

Accredited status does not imply endorsement by ACC of any commercial products displayed in conjunction with this activity.

ACCF reserves the right to modify faculty and program without notice.

Disclosure/Conflict of Interest:
As a provider jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), the American College of Cardiology Foundation (ACCF) must ensure balance, independence, objectivity, and scientific rigor in all of their directly provided or jointly provided/co-provided educational activities. Planners, presenters, and other contributors, in a position to control the content are required to disclose to the audience all relevant financial relationships he/she and/or his/her spouse or domestic partner may have, occurring within the past 24 months, with any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. When an unlabeled use of a commercial product or an investigational use not yet approved for any purpose is discussed during an educational activity, the contributor should disclose that the product is not labeled for the use under discussion or that the product is still investigational.

ACCF is committed to providing its learners with high-quality activities and materials that promote improvements and quality in health care and not a specific proprietary business or commercial interest. The intent of this disclosure is not to prevent participation in educational activities by persons with a financial or other relationship, but rather to provide learners with information on which they can make their own determination whether financial interests or relationships may influence the education activity.

ACCF assesses conflicts of interest (COI) with its faculty, planners, managers, staff, and other individuals who are in a position to control the content of certified activities. All relevant potential conflicts of interest that are identified are thoroughly vetted by course directors, ACCF education staff, and members of the Accreditation Compliance Workgroup (ACWG) through a process that includes appropriate peer review for fair balance, scientific objectivity and validity, and patient care and safety recommendations.

ACCF has taken the necessary steps to ensure that all relevant financial relationships have been mitigated.

Please note ACCF staff and the ACWG members involved with this activity have nothing to disclose.